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1. Introduction 
Diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia 
with disturbances of carbohydrate, fat and protein metabolism resulting from defect in 
insulin secretion, insulin action, or both. It is the leading cause of heart disease, adult 
blindness, and amputation of the lower extremities1. Diabetic patient suffer from a number 
of complications. Of these – hypertension, retinopathy, neuropathy, peripheral vascular 
disease – are most frequent ones and are responsible for considerable morbidity and 
mortality. Diabetic nephropathy (DN) is a chronic progressive kidney disease with high 
morbidity and mortality. There is a gradual loss of renal function ultimately leading to end 
stage renal disease (ESRD) where life is not sustainable without renal replacement therapy2. 
The course of DN is characterized by early elevation of arterial blood pressure, increasing 
albuminuria with gradual decline in glomerular filtration rate (GFR) of 10-12 ml.min-1.year-
13,4,5. The degree of albuminuria is closely related to the progression of DN6. Diabetic 
patients with nephrotic range proteinuria have the fastest decline in GFR7 and the shortest 
survival time8. 
Proteinuria has been considered an indicator of glomerular disease severity9. The proposed 
effects of proteinuria on the kidney include increased severity of glomerulosclerosis, 
tubulointerstitial inflammation, and subsequent fibrosis, thereby contributing to progressive 
renal function loss. These facts have permitted the establishment of a “proteinuria 
hypothesis” that consists of three postulates: higher levels of proteinuria predict adverse 
clinical outcomes; reduction of proteinuria correlates with slowing of renal progression; and 
proteinuria is a surrogate end point and target of clinical interventions10. 
Key to the development of DN is the hyperglycemic state, which has been postulated to 
mediate its effect in several different ways. First, glucose in sustained high concentrations 
may be directly toxic to cells, altering cell growth and gene and protein expression and 
increasing extracellular matrix and growth factor production11. Second, glucose may induce 
its effects indirectly through the formation of metabolic derivatives such as oxidants and 
glycation products12,13. Formation of advanced glycation end-products (AGES) may damage 
cells because of modifications to extracellular matrix proteins and to cellular proteins14. 
The renin-angiotensin-aldosterone system (RAAS) is a coordinate cascade of proteins and 
peptide hormones, the principal effector of which is angiotensin II. In kidney it is regulated 
via a self-contained renin angiotensin system in a paracrine fashion15. Renin is an enzyme 
produced by the kidney in response to a number of factors including adrenergic activity (ǃ1-
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receptor) and sodium depletion. Renin converts circulating glycoprotein, angiotensinogen, 
into the biologically a high potent vasoconstrictor angiotensin II16. 
Angiotensin II acts on the heart and the kidneys by binding to the G protein-coupled 
receptors type 1 and type 2. The angiotensin receptor type 1 mediates the more deleterious 
effects of angiotensin II – that is, vasoconstriction and cardiac and vessel hypertrophy17. 
In diabetes mellitus, local activation of the renin angiotensin system or increased intrarenal 
sensitivity to angiotensin II, especially angiotensin II receptor 1 occurs. Several studies have 
demonstrated that, in spite of normal or suppressed plasma renin activity, the intrarenal 
content of renin in increased. This increase can contribute to the progression of diabetic 
nephropathy via several hemodynamic, tubular and growth promoting actions18.  
Activation of the local renin angiotensin system also constricts the efferent more than the 
afferent arteriole. This glomerular hemodynamic change increases single nephron 
glomerular filtration rate in an attempt to maintain global glomerular filtration rate despite 
progressive loss of functioning nephrons in chronic kidney disease. However, if this change 
is sustained, it will likely result in glomerular injury and an accelerated loss of kidney 
function over time19. 
Angiotensin II is the main effector of the RAAS and exerts its vasoconstrictor effect 
predominantly on the postglomerular arterioles, thereby increasing the glomerular 
hydraulic pressure and the ultrafiltration of plasma proteins, effects that may contribute to 
the onset and progression of chronic renal damage. Angiotensin II may also directly 
contribute to accelerate renal damage by sustaining cell growth, inflammation, and fibrosis. 
Interventions that inhibit the activity of the RAAS are renoprotective and may slow or even 
halt the progression of chronic nepropathies17.  
A large number of studies established that progressive deterioration of renal function is the 
result of compensatory glomerular hemodynamic changes in response to nephron loss. In 
the widely used experimental model of renal mass reduction, the remaining nephrons 
undergo hypertrophy, reduced arterial resistance, and increased glomerular blood flow20. 
After nephron loss, the remaining nephrons develop glomerular capillary hypertension, and 
the single-nephron glomerular filtration rate (GFR) increase (hyperfiltration). These changes 
are thought to be adaptive in that they help to initially maintain the overall GFR. However, 
they have negative long-term effects and ultimately lead to renal insufficiency and ESRD. 
Podocytes are glomerular epithelia cells for glomerular structure and function, surrounding 
glomerular capillaries and forming foot processes contributing to the filtration barrier and 
providing structural stabilization. The diabetic kidney abnormally regulates intraglomerular 
pressure with imbalance between afferent and efferent arteriolar vasodilatation leading to a 
20 mmHg increase in glomerular pressure and allowing hypertension to be transmitted to 
the glomerulus21. 
Besides these glomerular hemodynamic effects, other studies have revealed several 
nonhemodynamic effects of angiotensin II that may also be important in renal disease 
progression. These findings have suggested that angiotensin II may alter permselective 
properties of the glomerular capillary barrier by mediating contraction of the foot processes, 
ultimately changing slit-diaphragm architecture and allowing proteins to escape more easily 
into the urinary space22. 
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Nonhemodynamic effects of angiotensin II include increased production of reactive oxygen 
species; upregulation of cytokines, cell adhesion molecules, and profibrotic growth factors; 
induction of transforming growth factor-ǃ (TGF-ǃ) expression, increased synthesis of 
extracellular matrix proteins; stimulation of plasminogen activator inhibitor-1 production by 
endothelial and vascular smooth muscle cells; and macrophage activations and infiltrations23. 
There is increasing evidence that TGF-ǃ is a major pro sclerotic mediator. Its production is 
stimulated by angiotensin II and by glucose directly. Preclinical studies have shown that 
TGF-ǃ blockade prevents and also ameliorates DN24,25. 
In addition, to amplify some of the effects of angiotensin II, aldosterone may also directly 
contribute to endothelial dysfunction, aldosterone may also remodel human endothelium in 
vitro by increasing the size and stiffness of endothelial cells, which favors leakage through 
intracellular gaps26. 
In animal models, high intraglomerular capillary pressure impairs the size-selective function 
of the glomerular permeability barrier and causes protein ultrafiltration27, 28. The secondary 
process of reabsorption of filtered proteins can contribute to renal interstitial injury by 
activating intracellular events. Local recruitment of macrophages by tubular cells that are 
loaded with ultrafiltered plasma proteins may contribute to interstitial fibrosis by engaging 
matrix-producing interstitial myofibroblasts. Macrophages also regulate matrix 
accumulation via release of growth factors, such as TGF-ǃ and platelet derived growth 
factor (PDGF). TGF-ǃ stimulates the transformation of interstitial cells into myofibroblasts. 
In addition proximal tubular epithelial cells communicate with interstitial fibroblasts to 
promote fibrogenesis via paracrine release of TGF-ǃ. In rats with remnant kidneys at day 14, 
after the onset of proteinuria, TGF-ǃ mRNA was upregulated in proximal tubular cells in 
parallel with early accumulation of the peritubular interstitium, suggesting that interstitiall 
fibroblasts are the initial target of profibrogenic signals elicited by protein 
overreabsorption29. Treatment of these rats with an angiotensin converting enzyme inhibitor 
(ACEI) at the same time limited excess protein overload and interstitial inflammatory cell 
infiltration and abrogated the abnormal TGF-ǃ 1 gene expression in tubular cells that in all 
likelihood was responsible of myofibroblasts in surrounding areas. ACEI exerts beneficial 
effects in the glomerulus primarily by preserving the permselective barrier to proteins30, 
thereby limiting proteinuria and filtered protein-dependent inflammatory and fibrogenic 
signals. The ACEI also may act locally by preventing nonhemodynamic effects of 
angiotensin II via apical angiotensin receptors on tubular cells, including renal cell 
proliferation and TGF-ǃ 1 expression31. 
In addition to albumin, transferring, and Immunoglobulin, glomerular proteinuria results in 
ultrafiltration of high molecular weight precursor forms or complexes of growth factor 
proteins such as insulin like growth factor 1, hepatocyte growth factor and TGF-ǃ 1. 
Inflammatory and vasoactive substances formed in excessive amounts by proximal tubuli 
are secreted toward the basolateral compartment of the cell and give rise to a inflammatory 
reaction in the interstitium that consistently precedes renal scarring. These processes can be 
accelerated by cytokines released by tubular epithelial cells and by inflammatory cells that 
accumulate in the interstitium when proteinuria is present32-36. 
Both interstitial inflammation and progression of disease can be controlled by such drugs as 
ACEI, which strengthen the glomerular permeability barrier to proteins and thereby limit 
proteinuria and filtered protein-dependent inflammatory signals37. 
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Lastly, the increased glomerular permeability may result in excess ultrafiltration of some 
complement protein fractions that may be directly toxic to proximal tubules and incite 
injury. In a subtotal nephrectomy model of renal insufficiency, C3 staining was associated 
with the appearance of interstitial infiltrated. Treatment with ACEI, which lowered 
proteinuria, also decreased C3 staining38. 
Recent studies utilizing transgenic rats with overexpression of the angiotensin II type 1 
receptor in podocytes revealed that increased angiotensin receptor type 1 signaling in 
podocytes leads to structural podocyte damage and protein leakage39. To support this 
finding from a therapeutic point of view, recent studies showed that ACEI and angiotensin 
receptor blocker (ARB) induce redistribution of the molecules in the slit diaphragm, which 
determine leakage of protein through glomerular filtration barrier40-42.  
There are some data showing that some of the beneficial effects of the RAAS blockade may 
be related to anti-inflammatory properties of ACEI and ARB43. In a clinical study, Stevinkel 
et al found low plasma levels of tumor necrosis factor-ǂ and C-reactive protein (CRP) in 
ESRD patients treated with ACEI44. The benefit seen with these drugs is beyond that which 
would be expected from their antihypertensive effects. 
The disassociation between doses needed to inhibit local tissue actions of angiotensin II and 
circulatory concentrations directly involved in blood pressure regulation may be due to 
reduced tissue penetration or higher tissue concentration of angiotensin II or its receptor45. 
Increased RAAS activity and augmented angiotensin II receptor density in the diseased 
renal tissue together with reduced penetration of the drug may explain that higher doses are 
needed for complete RAAS blockade in the tissue responsible for antiproteinuric effects as 
compared to circulatory levels regulating systemic blood pressure46. 
Several underlying mechanisms may explain the blood pressure independent 
antiproteinuric effects of agents blocking the RAAS47-50. These include reduced 
intraglomerular hydraulic pressure independent of systemic blood pressure by 
vasodilatation preferentially of the post glomerular arterioles51 and improved permselective  
properties of the glomerular membrane52. In addition, ARBs may prevent the occurrence of 
proteinuria by reducing the loss of glomerular nephrin53 and by reducing renal levels of 
prosclerotic cytokines such as TGF-ǃ and CTGF54. 
Doses of ACEI that exceed their maximal antihypertensive dose have not been examined 
adequately, because, ultrahigh doses of ACEI (doses above those approved for 
antihypertensive treatment according to the FDA and the European agency for the 
evaluation of medicinal products) was thought to be associated with serious side effects55-57. 
In contrast, ARB has tested over a wide range of doses, without showing an increase of side 
effects with ultrahigh doses. Various clinical studies support the notion that the dose of ARB 
is inversely related to proteinuria, independent of blood-pressure control58-61. 
2. Rationale for higher dose 
ACEI and ARB have been shown to reduce proteinuria, blood pressure and thereby 
retarded deteriorating kidney function in diabetic subjects. Doses of ACEI and ARB 
currently employed in clinical practice and even in experimental protocols are based 
essentially on the observation of the maximal effects of these drugs on blood pressure. 
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“Conventional” doses of these drugs may be insufficient to completely neutralize the 
anomalous activation of the RAAS, thus helping to explain their failure to achieve complete 
renal protection62. 
So far reno protective therapy has been administered in doses extrapolated from the 
treatment of essential hypertension, with doses that may be suboptimal for reno protection. 
Studies of dose-related efficacy of ACEI or ARBs with dose titration based upon achieving 
the maximum antiproteinuric effect for reno protection have not been adequately 
performed63. 
The full reno- and cardiovascular protective potential of agents blocking the RAAS may not 
be reached in patients with diabetic renal disease when recommended doses of these agents 
are extrapolated from their blood pressure-lowering properties, which is currently the case 
for all ACEI and ARBs used for renoprotection. By exceeding currently recommended 
maximal dose, it has been demonstrated that within the recommended dose interval higher 
doses provide greater antiproteinuric effects than lower doses64. 
Recent trials investigating the ability of these agents to protect patients against target organ 
damage have now repeatedly shown that the higher doses were most effective, thus 
recommending more aggressive treatment in future65.  
The study of the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study 
(IRMA-2) investigated the reversibility of kidney function changes after withdrawal of 2 
years’ antihypertensive treatment. They included 133 hypertensive type 2 diabetic patients 
with persistent microalbuminuria, randomized to double-masked treatment with either 
placebo, irbesartan 150 mg, or irbesartan 300 mg once daily for 2 years. Arterial blood 
pressure, overnight urinary albumin excretion rate, and glomerular filtration rate (GFR) 
were determined repeatedly. In IRMA-2 trial the benefit of protein reduction was 
maintained only in the group that was treated with the higher dose of Irbesartan 
300mg/day66. 
A double-masked randomized crossover trial included 52 (41 males) hypertensive type 2 
diabetic patients with microalbuminuria on ongoing antihypertensive medication. 
Following 2 months wash-out (baseline), patients were treated randomly with irbesartan 
300, 600, and 900 mg once daily, each dose for 2 months. This study by Rossing et al., 
revealed that ultrahigh dosing of irbesartan [900mg O.D (3 times higher maximal 
recommended dose)] was generally safe and offers additional nephroprotection 
independent of changes in systemic blood pressure and glomerular filtration rate in 
comparison to the currently recommended dose of 300mg46. In another study conducted by 
Andrei Forclaz et al., assessed the blockade of the rennin-angiotensin system (RAS) achieved 
with 2 angiotensin antagonists given either alone at different doses or with an ACE 
inhibitor. First, 20 normotensive subjects were randomly assigned to 100 mg Losartan once 
daily or 80 mg Telmisartan once daily for 1 week; during another week, the same dose of 
losartan and telmisartan were combined with 20 mg Lisinopril once daily. Then, 10 subjects 
were randomly assigned to 200 mg losartan once daily and 160 mg of Telmisartan once daily 
for 1 week and 100 mg losartan twice daily and 80 mg telmisartan twice daily during the 
second week. This study stated that the blockade of the renin angiotensin system (RAS) 
being only partial with 100mg Losartan and 80mg Telmisartan67. Previous studies with 
ACEI and angiotensin II receptor antagonists have shown that increasing the dose once 
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daily has little effect on the peak inhibition but tends to prolong the duration of the 
inhibition. In accordance with this observation increasing the dose of Losartan to 200mg (2 
times higher than maximal recommended dose) once daily and that of Telmisartan to 160mg 
once daily significantly improved the trough blockade68,69,70. Another study with a total of 
23 hypertensive patients with type 2 diabetes and nephropathy was carried out with four 
treatment periods, each lasting 2 months. This study stated that, albuminuria was reduced 
significantly more by Candesartan 16 and 32mg (recommended maximal dose) as compared 
with 8mg daily, without differences between the two highest doses45. Study with 64mg (2 
times maximal recommended dose) was more effective in reducing proteinuria in patients 
with chronic kidney disease than 16 and 32mg/day Candesartan71. Data from another study 
of 10 older patients with heavy proteinuria (>1.5 g/day) of different eitiology have 
suggested that additional reduction in proteinuria can be obtained by increasing the dose of 
Candesartan from 32 to 96mg (3 times maximal recommended dose) daily72. A recent short-
term safety study of 12 patients with various forms of chronic renal diseases with severe 
proteinuria also demonstrated good tolerability of the ARB Candesartan in doses 5 times 
higher than currently approved maximum dose58. 
Vogt et al., conducted study with Lisinopril 10, 20, 30 and 40mg/day (2 times higher the 
usual dose) in 12 (8 of whom were finally selected for the study) nondiabetic proteinuric 
patients. The eligible patients entered the run-in phase in which previous medication was 
replaced for the highest recommended daily dose irbesartan 300 mg combined with the 
diuretic hydrochlorothiazide 12.5 mg once daily. Then, patients with proteinuria >1 g/d and 
serum potassium concentration <5.5 mmol/L entered the phase of dose titration. In this 
phase, lisinopril was added in increasing daily doses to a maximum of 40 mg. All periods of 
treatment (run-in and up-titration) lasted at least 6 weeks. Their study concluded that, dose 
titration induced further reduction of residual proteinuria73. Fujihara et al., concluded that 
the renal protection afforded by ARB in renal ablation was dose dependent and maximal 
protection may require doses several fold higher than those currently employed. In rat 
model, treatment with Losartan at a dose 10 fold higher than dose 50mg/kg/day and 50 
fold higher than those usually employed in experimental studies, arrested the progression of 
both glomerulosclerosis and interstitial expansion. This dose dependence of Losartan is 
likely to be observed in human as well, since clinical studies showed that the human 
responses can be predicted with reasonable accuracy from animal experiments62. The effects 
of different dosage of ramipril, from a minimum of 5mg/day to a maximum of 20 mg/day 
(4 times the recommended maximum dosage) were evaluated on the level of proteinuria. 
Although the higher dosage had no additional effect on blood pressure, urinary protein 
excretion rates were further reduced37. 
In a study by Ruggenenti P, uptitration of lisinopril from 10 to 40 mg was done in 28 
patients with nondiabetic chronic nephropathies. These patients entered 4-week lisinopril 
uptitration periods (from 10, to 20, 30, and 40 mg/d), followed by a 6-week backtitration 
period to lisinopril 10 mg/d and 4-week recovery period (lisinopril withdrawal). Maximum 
lisinopril doses significantly and safely reduced proteinuria, serum total, LDL cholesterol, 
and triglycerides without substantially affecting serum HDL and renal hemodynamics74. 
More recently in a preliminary report, Schjoedt et al.75 studied 56 patients with type 1 
diabetes and nephropathy, who in a double masked crossover trial received 20, 40 or 60 
mg/day of lisinopril. The 40 mg/day dose provided a great antiproteinuric effect than 20 
mg/day but 60 mg/day did not afford further renoprotection.  
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Tang et al., in their study on 75 patients with chronic heart failure with low Enalapril (5 mg) 
dose and high dose (40 mg) over six months and found that there was not any significant 
reduction in systolic and diastolic blood pressure between the two dose groups. They also 
measured serum aldosterone and angiotensin II levels in their study and they observed that 
these renin system hormones weren’t adequately suppressed even with the higher dose76. 
Most studies that showed effective reduction of blood pressure and proteinuria included 
mostly normotensive and/ or microalbuminuric group of patients. In the study conducted 
by Adrienne et al.,77 the antiproteinuric effects of losartan in 147 normotensive patients with 
type 2 diabetes and microalbuminuria was assessed. The losartan dose was 50 mg during 
the first 5 weeks and 100 mg during the subsequent 5 weeks. A significant 25% relative 
reduction in the albumin excretion rate occurred after 5 weeks of the 50 mg losartan dose, 
with further improvement over the subsequent 5 weeks with the 100 mg dose. Losartan was 
safe and well tolerated in these normotensive patients.  
Lacouriciere et al.,78 in their studies after using Losartan and Enalapril found significantly 
decreased blood pressure in hypetensive type 2 diabetics with early nephropathy. The study 
was a one-year prospective, double blind trial with losartan and enalapril administered 
alone or in combination with hydrochlorothiazide and other antihypertensive agents. 
Arterial Blood Pressure and renal and biochemical parameters were measured at baseline 
and after 12, 28, and 52 weeks of active treatment. 92 hypertensive type 2 diabetics with 
early nephropathy completed the study. 
It may be possible that advanced renal failure patients with proteinuria may not respond to 
increasing doses of Enalapril. Similar findings were also seen by Jensen et al.,79. They 
conducted study with normal to high Enalapril dose (5 to 40 mg) including 
macroproteinuric patients with advanced renal insufficiency of variable etiologies. They 
found that at study end blood pressure and proteinuria didn’t change significantly in both 
dose groups. 
Anderson et al.,63 in their study with 50 consecutive hypertensive type 1 diabetic patients 
with diabetic nephropathy received increasing doses of losartan 50, 100, and 150 mg once 
daily in three periods each lasting 2 months. Using Losartan from 50 to 150 mg among 
macroproteinuric patients with normal renal function found that maximum antiproteinuric 
effect was at 100 mg dose without any adverse effect at 150 mg. No significant benefit of 
increasing dose from 100 to 150 mg was observed in their study groups. 
Huo et al.,80 undertook a study with Losartan starting with 50 mg and then increasing to 200 
mg in a total 360 proteinuric nephropathy patients for a period of 3 years and found 
significant reduction in blood pressure and proteinuria. But in their study, to control blood 
pressure, concomitant antihypertensive drugs were used in their patients. It may be possible 
that antihypertensive drugs in Hou’s study reduced blood pressure significantly which 
influenced the proteinuria reduction to a significant level unlike ours. 
Woo et al.,81 carried out a study in nondiabetic proteinuric subjects with renal dysfunction 
using 10 mg Enalapril and 100 mg Losartan. 41 patients with biopsy-proven IgAN entered 
a control trial, with 21 in the treatment group and 20 in the control group. Patients in the 
treatment group received ACEI/ATRA or both with 3 monthly increases in dosage. They 
found that blood pressure or proteinuria was reduced only in 30% to 50 % patients. The 
non responder patients were those who had heavy proteinuria (>2 g/day) and more 
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advanced renal dysfunction (serum creatinine > 2.5 mg/dl). Study results indicate that 
combination of heavy proteinuria with advanced renal impairment may be less or non 
responsive to angiotensin converting enzyme inhibitors or angiotensin receptor blocker 
even at higher doses. 
Rocca et al.,82 in 45 chronic heart failure patients showed increasing dose of Enalapril from 
5 to 40 mg reduced blood pressure more and cough was more common on highest than 
lowest dose. The dosage was changed three times to treat all patients with lower, higher, 
and finally, the initial dosage for 4 weeks each. Within patient comparison revealed that 
serum potassium and creatinine were higher on the highest than the lowest dose. The 
patient’s included in that trial were suffering from chronic heart failure and were 
primarily non diabetic and non proteinuric patients. It is possible that these patients are 
more susceptible to adverse effect with increasing doses of angiotensin converting 
enzyme inhibitor. 
Brenner et al.,83 conducted a study with a total 1513 patients having hypertension, type 2 
DM and nephropathy (S. cr 1.3-3 mg/dl) for a mean of 3.4 years. A total of 327 patients in 
the losartan group reached the primary end point, as compared with 359 in the placebo 
group. Their study established that losartan, along with conventional antihypertensive 
treatment as needed, conferred strong renal protection in these patients. The risk of the 
primary end point a composite of doubling of the S. creatinine concentration, ESRD was 
reduced by 25% & 28% respectively with losartan but had no effect on the rate of death. The 
level of proteinuria declined by 35% with losartan. 
3. Safety monitoring 
Enalapril was well tolerated even at 40mg (maximal recommended dose) once daily dose, as 
compared with 5mg once daily dose. In fact, there were more reported adverse events and 
death (requiring withdrawal from the trial) in the low-dose group than in the high-dose 
group. As seen in previous studies, a large proportion of patients with advanced chronic 
heart failure could receive up to very high doses of Lisinopril (medium-dose 12.5 or 15.0 mg 
once daily for 2 to 4 weeks and then randomized to high 35.0 or 32.5 mg once daily or low-
dose 5.0 or 2.5 mg once daily) and Enalapril without significantly more adverse effects84,85. 
Losartan could be administered at an extremely high dose without any perceptible toxic 
effect. In rat model, treated with 500mg/kg/day, had no hypotension and plasma K+ 
concentration was not higher63. In the trial with lisinopril (where a total of 3164 patients 
were assigned randomly with either low dose of 2.5 to 5.0 mg daily lisinopril in 1596 
patients or high doses of 32.5 to 35 mg daily lisinopril to 1568 patients for 39 to 58 months), 
increase in serum creatinine in the high-dose group (35mg/day) was slightly greater than 
in the low-dose group (5mg/day), but the number of patients with major increase in 
serum creatinine (>1mg/dl) was not different86. There was a therapy with Candesartan 8, 
16, 32mg (maximal recommended dose) in a total of 23 hypertensive patients with type 2 
diabetes and nephropathy with four treatment periods, each lasting for 2 months. The 
therapy was well tolerated without associated adverse events. A slight increase in serum 
K+ was found, but no incidence of hyperkalamia and hypotension was observed in these 
patients45. No serious adverse event was reported in relation to the ultrahigh dose (64mg 
i.e.2 times maximal recommended dose) of candesartan. This confirmed previous studies 
observing no dose-response curves of serious adverse effect of increasing dose of ARB70. 
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In a pilot study, 12 patients (10 males; age = 57± 14 years) with a history of diabetic or 
non-diabetic chronic kidney disease received candesartan in an 8-week open-label trial in 
which drug was titrated to a targeted dosage of 160 mg/day (5 times above the currently 
approved maximum dose) and remained at that dosage for the subsequent 4 weeks. 
Candesartan was well tolerated with no serious drug-related adverse events reported. 
Serum creatinine concentrations throughout the study were not different from baseline 
levels. Plasma potassium concentrations at 160 mg/day candesartan were similar to those 
at baseline. The results of this pilot study suggest that supramaximal doses of ARBs are 
safe and well tolerated in patients with chronic kidney disease, while reducing both blood 
pressure and proteinuria58. 
In Irbesartan Diabetic Nephropathy Trial (IDNT), Irbesartan (titrated to 300mg/day i.e. 
maximal recommended dose) slowed the deterioration of renal function by decreasing risk 
of doubling of serum creatinine, development of end stage renal disease, or death by 20%. 
Fewer patients receiving Irbesartan had a doubling of their serum creatinine concentration 
than placebo87. 
Treatment with Irbesartan was carried out in 52 (41 males) hypertensive type 2 diabetic 
patients with microalbuminuria. Following 2 months of wash-out (baseline), patients were 
treated randomly with irbesartan 300, 600, and 900mg/day (3 times higher maximal 
recommended dose), each dose for 2 months. The therapy induced an increase in plasma K+ 
and these changes were only marginally greater when exceeding the currently 
recommended dose of Irbesartan. None of the patients developed hyperkalemia46.  
In RENAAL (Reduction of Endpoints in NIDDM with the AngiotensinII II Antagonist 
Losartan) study, 50 consecutive hypertensive type 1 diabetic patients with diabetic 
nephropathy received increasing dose of losartan, 50, 100, and 150 mg once daily in three 
periods each lasting 2 months. Losartan 50mg to 100mg reduced the primary end point 
(doubling of baseline serum creatinine, end stage renal disease, or death). Potassium, 
sodium, and cholesterol, including HDL-cholesterol, remained unchanged at 50, 100 and 
150mg/day with Losartan. Levels of uric acid in serum did not exceed the upper normal 
range in this study63.  
Serum K+ and serum creatinine were slightly, higher at high [40mg/day (4 times the 
recommended dose)] than at low (10mg/day) enalapril levels. Most patients show an only 
mild increase in serum creatinine, and ACEI therapy did not have to be discontinued in 
these patients. An increase in enalapril dose did not lead to hyperkalemia. Serious adverse 
events (i.e. worsening of chronic heart failure, anuria and serious arrhythmia) tended to be 
more common after downward than after upward titration of enalapril82. In the ValHeft 
(Valsartan in Heart Failure) trial, patients received 160mg valsartan twice daily without any 
serious adverse effect88. In a study by Hou et al. , the incidence of cough was significantly 
higher in the benazepril arm as compared to losartan arm, but it did not seem to be dosage 
related. Hyperkalemia occurred in eight (4.4%) patients in the benazepril arm and eight 
(4.4%) patients in the losartan arm. Of these 16 patients, six were successfully treated with 
dietary modification, concomitant diuretic therapy, and optimized acid-base balance. The 
remaining 10 patients withdrew from the study80. In the study with ultrahigh dose of 
Irbesartan (900 mg) total 58 patients having hypertension, type 2 diabetes mellitus with 
microalbuminuria (persistent Urinary Albumin Excretion between 30 & 300 mg/24hours) on 
ongoing antihypertensive (wash out done) were included. 4 patients were excluded due to 
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adverse clinical events, which were not considered related to the study medication. 1 patient 
discontinued the study after 2 weeks on Irbesartan 900 mg before any clinical examination 
was performed due to complaints of dizziness & general discomfort. Among 52 patients 
completing the study, 7 patients complained of mild & transient dizziness, 1 patient during 
300 mg, 3 patients during 600 mg & 3 during 900 mg. There was a significant increase in 
plasma K+ of 0.3 mmol/L during treatment with irbesartan 300 & 600 mg & by 0.4 mmol/L 
during treatment with 900 mg. However, none of the patients included in the study 
developed hyperkalemia (plasma K+> 5.5 mmol/L). Plasma hemoglobin decreased 
significantly from 8.7 mmo/L at baseline to 8.2 mmol/L during treatment with 300 & 600 
mg & to 8.1 mmol/L during irbesartan 900 mg46. 
4. Dual blockage of RAAS with ACEIs and ARBs 
An insufficient response to ACE inhibition might be explained by the incomplete blockade 
of the RAS obtained with ACE inhibitors, which are unable to block completely the 
formation of angiotensin II (Ang II), because some generation of Ang II is produced via 
other non-ACE pathways89. Furthermore, Ang II levels return to normal values after chronic 
therapy with ACE inhibition, the so-called “ACE escape phenomenon”90. 
The demonstration of local angiotensin II (Ang II) synthesis in numerous tissues and organs 
has led to the concept of local or tissue-based RAASs that are independent of but can 
interact with the traditional circulating RAAS91. These local RAASs appear to act in a 
paracrine/autocrine manner to regulate organ function and are involved in pathologic 
events associated with end-organ damage. The kidney contains all the elements of the 
RAAS, and intrarenal formation of Ang II independent of the circulating RAAS was first 
demonstrated more than 30 years ago92. 
Local AngII in the kidney has multiple roles contributing in hypertension and kidney 
damage. It enhances capillary filtration pressure, directly by efferent arterial 
vasoconstriction and indirectly through TGF-ǃ1 (transforming growth factor beta1) 
mediated impaired afferent arteriole autoregulation93. AngII decreases the synthesis of 
negatively charged proteoglycans and suppresses nephrin transcription94, 95, which results in 
podocyte apoptosis. Through VEGF (vascular endothelial growth factor) and TGF-ǃ1, 
induces synthesis of the ǂ3 chain of collagen type IV, the principal ingredient of the 
glomerular basement membrane96, stimulates upregulation of adhesion molecules such as 
vascular cellular adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-
1), and integrins, allowing circulating immune cells to adhere on capillaries. Ang II induces 
nuclear factor Κǃ (NF-κB) –mediated transcription of chemokines, including monocyte 
chemoattractant protein-1 (MCP-1), RANTES, and others, resulting in renal tissue 
infiltration with leukocytes and also induces plasminogen activator inhibitor-1 (PAI-1) and 
tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) which inhibits metalloproteinases 
resulting in accumulation of extracellular matrix. Through all these mechanisms, AngII 
induces proteinuria, inflammation, growth effects, apoptosis and fibrosis97. 
Chymase-dependent Ang II formation may be at least partly responsible for ‘ACE escape’. 
This term refers to the observation that, in a high proportion of patients chronically treated 
with ACE inhibitors, Ang II levels gradually return to baseline after an initial decline. This 
increase in Ang II formation in the presence of ACE inhibitors is likely due to a compensatory 
increase in plasma renin activity (PRA) caused by disruption of the feedback loop by which 
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AngII normally inhibits renin release98. Under these circumstances, Ang II can be formed from 
Ang I by alternative, ACE-independent pathways, such as chymase, which has been shown to 
be upregulated in diabetic and hypertension-related nephropathies99. 
ACE-I inhibits the angiotensin-converting enzyme (ACE), thereby reducing the synthesis 
of Ag II. In addition, it inhibits the degradation of bradykinin, a vasodilator that 
stimulates nitric oxide, prostaglandin E2, prostacyclin and cyclic guanosine 
monophosphate production. This might confer additional renal protection, beyond that 
achieved by the inhibition of Ag II. However, with prolonged ACE-I therapy, the Ag II 
level can increase through an escape mechanism via peripheral chymase action89,99. ARB, 
on the other hand, acts directly on the Ag II type 1 receptor (AT 1) and thus blocks all the 
known actions of Ag II. In addition, by blocking AT 1, it provides unopposed stimulation 
of the Ag II type 2 receptor (AT 2) in the kidney. Stimulation of the AT 2 receptor has been 
associated with increased nitric oxide production, increased natriuresis as well as growth 
inhibitory effects100. In order to take advantage of the distinct properties of both these 
medications, a number of studies have explored the possibility of dual blockade of the 
RAAS with ACE-I and ARB. 
In the search of new alternatives that could improve the antiproteinuric and 
nephroprotective effects of RAS blockers, we believe that the association of ACE inhibitors 
and ARB might prove useful. ARB produces a complete blockade of the RAS and stimulates 
the vasodilating and non-proliferative actions of Ang II via the AT2 receptor101. 
Furthermore, ACE inhibitors, but not ARB, inhibit the metabolism of kinins, which increases 
the levels of bradykinin, also a potent vasodilator102. 
Recently, some authors have reported a superior effect of the combination of ACE inhibition 
and ARB on microalbuminuria and on clinical proteinuria in patients with primary 
nephropathies103-105, and in type 1 and type 2 diabetic patients106, 107. 
The rationale for combined therapy with ACE inhibitors and ARB is based on the different 
mechanism of these two drugs in the RAS blockade. Both drugs inhibit the action of Ang II. 
It is known that Ang II plays a pivotal role in the pathophysiological course of renal disease 
progression. ACE inhibition could not completely inhibit the generation of Ang II, which 
may be produced via other non-ACE pathways89. In contrast, ARB completely abolishes the 
action of Ang II through blockading theAT1 receptor, producing an accumulation of Ang II 
that stimulates the vasodilatory and antiproliferative actions of Ang II mediated through the 
AT2 receptor101. On the other hand, ACE inhibitors but not ARB, decreases degradation of 
bradykinin, which is a potent vasodilator102. 
A recent meta-analysis by Jennings et al reported a greater reduction in proteinuria with 
combination therapy when compared with ACE-I alone108. The response to treatment with 
ACE-I and ARB may differ among different races109. 
Mogensen et al studied 197 hypertensive patients with type 2 DM and microproteinuria, and 
found that combination therapy with once daily candesartan 16 mg and lisinopril 20 mg was 
more effective in reducing BP and albuminuria than monotherapy with either drug alone106. 
Cetinkaya et al found that a combination of enalapril 10 mg daily and losartan 50 mg daily 
decreased both the proteinuria and MAP by a greater extent when compared with the 
administration of either drug alone110. 
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In two separate randomised double-blind crossover studies, Rossing et al found a further 
reduction in albuminuria when candesartan 16 mg was added to the pre-existing ACE-I 
therapy in hypertensive type 2 diabetic patients. In the first study involving 18 type 2 
diabetic patients who were taking the recommended doses of ACE-I, corresponding to 20 
mg of enalapril/lisinopril once daily or 100 mg of captopril daily, the administration of 
candesartan 16 mg daily for two months induced a 25% reduction in albuminuria, together 
with a 10 mmHg reduction in 24-hour systolic BP111. In the second study involving 20 type 2 
diabetic patients on a maximal recommended dose of ACE-I (enalapril/lisinopril 40 mg 
daily or captopril 150 mg daily), there was a further 28% significant reduction in 
albuminuria, and a modest but non-significant reduction in BP after two months of being 
administered candesartan at 16 mg daily112. On the other hand, the addition of Losartan 50 
mg daily for one month did not improve proteinuria in 16 obese, hypertensive patients (12 
with diabetic nephropathy) with moderately advanced renal failure and heavy proteinuria 
(mean urinary protein 3.8 g/day)113. A Korean group also reported no beneficial effect on 
proteinuria when candesartan was added to ramipril therapy in type 2 diabetic patients 
with nephropathy despite the positive anti-proteinuric effect seen in patients with IgA 
nephropathy following the same regimen114, 115. 
Dual blockade of RAAS at different steps with ACEI and ARB would be an attractive 
alternative.  
In meta-analysis, Doulton et al demonstrated that combination therapy provided a further 
30%- 39% drop in proteinuria compared to monotherapy116 and in MacKinnon et al resulted 
in a significant decline in proteinuria both in diabetic and nondiabetic patients with a slight 
but significant increase in potassium, and an insignificant drop in GFR117. 
The IMPROVE (Irbesartan in the Management of Proteinuric Patients at High Risk for 
Vascular Events) study has shown no further benefit on albuminuria reduction in patients 
treated with combination therapy despite the fact that BP reduction was slightly better in 
the combination group. Subgroup analyses showed the largest reduction in albuminuria 
occurred in patients with overt nephropathy but it did not reach statistical significance118. 
In contrast to these studies, the VALERIA (Valsartan in Combination With Lisinopril Versus 
the Respective High Dose Monotherapies in Hypertensive Patients With Microalbuminuria) 
trial demonstrated that combination therapy was more effective in reducing 
microalbuminuria despite the fact that patients received the maximal recommended doses 
of lisinopril or valsartan as monotherapy119. 
5. Direct renin inhibition 
Aliskiren is the first orally active Direct Renin Inhibitor (DRI) to receive regulatory approval 
for hypertension. By inhibiting the enzymatic conversion by renin of Angiotensinogen to 
Angiotensin I, DRIs inhibit the initial and rate-limiting step in the RAAS cascade, thus 
reducing the product ion of al l downstream products derived from Angiotensin120, 121. 
Furthermore, in both clinical studies122 and in experimental animals123, aliskiren reduces 
plasma and/or urinary excretion of aldosterone. The role of aldosterone in endothelial 
dysfunction, inflammation, proteinuria and fibrosis is well known97. 
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Fig. 1. Effect of increased glomerular permeability to proteins on progressive renal injury 
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The mechanisms by which aliskiren may impart renoprotection are still under 
investigation. However, a number of possible mechanisms can be envisioned. First, 
aliskiren not only inhibits renin but also inhibits the activity of prorenin124 following its 
non-proteolytic activation upon binding to the (pro)renin receptor125. This may be of 
particular importance in diabetes in which prorenin levels are elevated and may 
contribute to local Ang II formation126. Second, aliskiren blocks the circulating RAAS and 
lowers blood pressure127. Hypertension is one of the most common comorbidities in CKD 
and its control is essential in reducing further renal damage and cardiovascular risk in 
CKD patients128. Third, aliskiren blocks the intrarenal RAAS and lowers renal Ang I and 
Ang II levels129, thus reducing the deleterious renal effects of Ang II97 (fig. 1). Finally, 
aliskiren has been shown to reduce the renal expression of the (pro)renin receptor in an 
animal model of diabetes124. If the (pro)renin receptor plays a role in CKD, 
downregulation of this receptor may reduce the Ang II-independent effects of (pro)renin 
receptor activation on renal fibrotic pathways130 ( Fig. 3 ). 
 
 
 
 
 
 
 
 
 
Fig. 2. Final common pathway for progression of chronic renal disease 
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Fig. 3. Multiple role of the Renin angiotensin aldosterone system in the pathogenesis of 
chronic kidney disease 
In patients who have vascular disease or high risk diabetes without heart failure, 
angiotensin-converting-enzyme inhibitors reduce mortality and morbidity from 
cardiovascular causes, but the role of angiotensin-receptor blockers in such patients is 
unknown. The Ongoing Telmisartan Alone and in Combination with Ramipril Global 
Endpoint Trial (ONTARGET) was carried out for the comparative study between ramipril, 
telmisartan and the combination of both in patients with vascular disease or high risk 
diabetes. After a 3 week, single-blind run-in period, patients underwent double-blind 
randomization, with 8576 assigned to receive 10 mg of ramipri per day, 8542 assigned to 
receive 80 mg telmisartan per day, and 8502 assigned to receive both drugs (combination 
therapy). Telmisartan was equivalent to ramipril in patients with vascular disease or high 
risk diabetes and was associated with less angioedema. The combination of the two drugs 
was associated with more adverse events without an increase in benefit131. 
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Fig. 4. Mechanism of  proteinuria in diabetic nephropathy 
 
Stage Glomerular 
Filtration Rate 
Urinary albumin 
excretion 
(mg/d) 
Blood 
pressure 
Years after 
diagnosis 
i. Hyperfiltration Supernormal <30 Normal 0 
ii. Microalbuminuria High normal 
To 
normal 
30-300 Rising 5-15 
iii. Proteinuria Normal 
To decreasing 
>300 Elevated 10-20 
iv. Progressive 
nephropathy 
Decreasing Increasing Elevated 15-20 
v. End stage renal disease <15ml/min Nephrotic Elevated 20-30 
Table 1. Stages of Diabetic Nephropathy 
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Fig. 5. Pathogenesis of Diabetic nephropathy 
6. Conclusion 
ACE inhibitors and ARBs, as monotherapy or in combination, have evolved as accepted 
first-line agents for delaying the progression of diabetic nephropathy. Currently, 
recommendations favor ACE inhibitors for type 1 and ARBs or ACE inhibitors for type 2 
diabetes as a result of large, controlled clinical trials. Therapeutic goals should be addressed 
not only for BP reduction, but in diminishing albuminuria as well. In subjects with 
microalbuminuria, the dose of ARBs or ACE inhibitors should be titrated by the clinician 
until normoalbuminuria is induced, even if supramaximal doses or a combination of ARBs 
and ACE inhibitors are necessary. There is evidence that achieving reduction in both 
microalbuminuria and in heavy proteinuria at greater doses than those used to control BP 
may be required using monotherapy or a combination of these RAS blockers132.  
Different studies showed that higher doses of angiotensin converting enzyme inhibitors and 
angiotensin receptor blocker are safer and beneficial. Rationale to use higher doses of 
angiotensin converting enzyme inhibitors or angiotensin receptor blocker is not only to 
reduce proteinuria and or to control blood pressure. Additional beneficial effects are 
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observed at higher doses other than renal systems. Losartan showed cardio protection by 
cardiac remodeling, vascular remodeling, atherosclerosis, endothelial function, inhibition of 
thrombus formation and platelet aggregation, reduction of risk factor for stroke in addition 
to renal effects133.  
Higher drug doses can reduce nephrotoxic components like TGF ǃ134, connective tissue 
growth factor135, inflammatory mediators like cytokines63 etc. It is evident that, these drugs, 
even when do not reduce proteinuria or blood pressure significantly, may provide the 
additional renoprotection with higher doses. 
Dual blockade of the RAS provides superior short-term renoprotection independent of 
systemic blood pressure changes in comparison with maximally recommended doses of 
ACEI in patients with type 2 diabetes as well as nephropathy. 
The ability of these two therapeutic agents to synergistically antagonize the RAAS can also 
be explained by their complimentary mechanisms of action. For example, ACE inhibition 
leads to a prolonged half-life of bradykinin, a potent vasodilator believed to be 
renoprotective. ARBs do not increase the half-life of bradykinin. They can further ablate the 
damaging effects resulting from the production of angiotensin II by non-ACE pathways, 
which is not completely blocked by an ACEI. Thus, it seems plausible that combining these 
two agents could more effectively oppose the RAAS than either agent alone136. 
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